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Background: Industry partnerships can help leverage resources to advance HIV/AIDS vaccine research, service
delivery, and policy advocacy goals. This often involves capacity building for international and local non-
governmental organizations (NGOs). International volunteering is increasingly being used as a capacity building
strategy, yet little is known about how corporate volunteers help to improve performance of NGOs in the fight
against HIV/AIDS.
Methods: This case study helps to extend our understanding by analyzing how the Pfizer Global Health Fellows
(GHF) program helped develop capacity of the International AIDS Vaccine Initiative (IAVI), looking specifically at
Fellowship activities in South Africa, Kenya, and Uganda. From 2005–2009, 8 Pfizer GHF worked with IAVI and local
research centers to strengthen capacity to conduct and monitor vaccine trials to meet international standards and
expand trial activities. Data collection for the case study included review of Fellow job descriptions, online journals,
evaluation reports, and interviews with Fellows and IAVI staff. Qualitative methods were used to analyze factors
which influenced the process and outcomes of capacity strengthening.
Results: Fellows filled critical short-term expert staffing needs at IAVI as well as providing technical assistance and
staff development activities. Capacity building included assistance in establishing operating procedures for the
start-up period of research centers; training staff in Good Clinical Practice (GCP); developing monitoring capacity
(staff and systems) to assure that centers are audit-ready at all times; and strategic planning for data management
systems. Factors key to the success of volunteering partnerships included similarities in mission between the
corporate and NGO partners, expertise and experience of Fellows, and attitudes of partner organization staff.
Conclusion: By developing standard operating procedures, ensuring that monitoring and regulatory compliance
systems were in place, training African investigators and community members, and engaging in other systems
strengthening activities, the GHF program helped IAVI to accelerate vaccine development activities in the field, and
to develop the organization’s capacity to manage change in the future. Our study suggests that a program of
sustained corporate volunteering over several years may increase organizational learning and trust, leading to
stronger capacity to advance and achieve NGO goals.* Correspondence: tvian@bu.edu
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Sub-Saharan Africa is more heavily affected by HIV/
AIDS than any other region in the world. More than
34 million HIV infected individuals live in East and
Southern Africa alone [1]. Governments, non-govern-
mental organizations (NGOs), citizen groups, and pri-
vate industry all have an interest in stopping the spread
of HIV in the region. Many are combining their efforts
through partnerships designed to respond to the myriad
challenges of research, service delivery, and policy advo-
cacy [2,3]. Research partnerships face many challenges, in-
cluding scarce research capacity, team work problems,
logistical constraints, communication, and difficulties re-
lated to partner and community buy in and trust [4-7]. Ef-
fective partnerships therefore require investments in
capacity building for international and local partners [8,9].
Capacity building is defined as “a process that im-
proves the ability of a person, group, organization or sys-
tem to meet its objectives or to perform better” [10].
Capacity building increases the ability and commitment
to take effective action. Approaches to build capacity
include financial and material support; organizational
development activities to strengthen structures and insti-
tutional standard practices which enable smooth and ef-
fective running of operations or research projects; and
building up of skills, confidence, and staff knowledge
[5-7,11]. Capacity building activities are more successful
when based on initial assessment of existing strengths
and weaknesses; designed for sustainability over the
long-term (e.g. training efforts also extend to stronger
supervision, mentoring, and career development); and
based on mutual respect and shared interests of the
partners involved [4,5,9,11-13]. A key lesson learned
from the literature is that capacity building is multifa-
ceted, and neither cheap nor fast.
International volunteering is increasingly being used as a
capacity building strategy [14,15]. Lough, et al. and others
theorize that capacity building activities will lead organiza-
tions to greater performance and sustainability, often with
reciprocal benefits for the volunteers themselves [15-17].
Benefits of capacity building in research include increases
in successful grant applications, publications, dissemin-
ation activities, and influence of research findings on
health policies and practice guidelines [11].
Yet, several factors make it hard to measure results in
capacity building [10,18-20]. First, capacity is dynamic
and continuous, so it cannot be easily measured using
cross-sectional surveys. It is multidimensional, affecting
variables at the system, organizational, and individual
level. And capacity is very dependent on local context
and the influence of the external environment [4,8]. In
addition to these difficulties, it is not easy to determine
the links between specific capacity building strategies
and results. Changes in capacity may not proceed in alinear fashion and are shaped by interacting forces and
actors [21]. Few studies to date have explored inter-
national volunteering as a capacity building strategy or
attempted to show how it may help improve perform-
ance in the fight against HIV/AIDS.
To help fill this gap, we examined a partnership to
promote capacity building through international cor-
porate volunteering (ICV). This partnership brought
employees from Pfizer Corporation, a multinational
pharmaceutical company with over 116,000 employees,
to work with the International AIDS Vaccine Institute
(IAVI), an international NGO with 200 staff, to further
the development of safe and effective vaccines to prevent
AIDS. The case study describes how the Global Health
Fellows (GHF) program helped develop capacity in IAVI
and local partner organizations, looking specifically at
eight Fellows who volunteered in South Africa, Kenya,
and Uganda. After providing some background on the
Pfizer GHF program and IAVI, the case describes
capacity-building activities undertaken from 2005 to
2009, and the impact of those activities. While it is diffi-
cult to attribute changes to any single factor, our study
suggests that a program of sustained volunteering may
increase organizational learning, which in turn helps to
strengthen organizational capacity for vaccine research.
The findings also will suggest how contextual variables
affect this process.
Pfizer Corporation’s GHF program is one of the first
and most comprehensive ICV programs in the health
sector [22-25]. Started in 2002, by 2010 over 250 Fellows
had worked in 40 countries. Fellows are screened and
selected to participate in the program through a com-
petitive process at Pfizer. Partner organizations work
with GHF staff to design the scope of work for the 3 to
6 month assignments and to choose a Fellow best
matched to the assignment based on skills and experi-
ence. Pfizer then orients Fellows through a program
which covers health, security, logistics, and cross-
cultural management. During their assignment, the
Fellow’s salary and benefits are paid from the budget of
his or her work unit, while living allowance and travel
costs are paid by the GHF program within Pfizer [23].
Started in 1999, IAVI works with partners in 25 coun-
tries and had an annual budget of nearly $84 million
from 2005–2009. IAVI operates as a product develop-
ment partnership (PDP), working closely with pharma-
ceutical companies, clinical research centers, and other
partners to develop support for collaborative efforts to
develop an AIDS vaccine a. Its scientific teams, located
on four continents, conduct research, develop products,
and perform observational studies and sponsor clinical
trials in partnership with more than 40 academic,
commercial and government institutions. An important
component of IAVI’s strategy is to conduct vaccine
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ticularly in East and Southern Africa. Table 1 summa-
rizes the types of research studies and clinical trials
which contribute to vaccine development.
International standards for clinical trials are rigorous,
and the same standards are applied whether participants
are being enrolled in trials in Uganda, the United States,
or any other country. This presents a challenge for
vaccine research in low-resource settings where organi-
zational capacity is often under-resourced. Lack of infra-
structure for communications, shortages of trained
personnel, and lack of community awareness are just
some of the problems which research institutions in
Africa must overcome in order to conduct vaccine trials.
Efforts to address these problems are further challenged
by the need to consider cultural values and community
expectations related to vaccines.
Over a period of five years, from 2005–2009, 12 Pfizer
GHF worked with IAVI and IAVI’s partners. Employees
from Pfizer’s research divisions were selected for volun-
teer assignments with IAVI in South Africa, Uganda,
and Kenya. The partnership between the two organiza-
tions had two goals: first, to help IAVI strengthen the
capacity of its local partners to enable them to conduct
vaccine trials meeting international standards; and sec-
ondly, to stimulate organizational learning within IAVI
so the organization could continuously improve its abil-
ity to coordinate and manage an ever increasing portfolioTable 1 Descriptions of Research Studies and Clinical
Trials
Study Description
Observational study A study where researchers are learning
about HIV/AIDS without actually testing
a drug or other intervention. Such a study
might involve drawing blood from trial
participants over time, to understand
characteristics of non-infected individuals
and to observe what happens at the cellular
level when they become infected.
Pre-clinical trials Studies of vaccines or treatment which are
carried out in animals.
Clinical trials
Phase I Researchers test a vaccine in a small group
of people (20–80) to determine how a drug
should be given, how many doses are needed,
and whether it is safe
Phase II Experimental vaccine is given to a larger group
of people (100–300) to see if it is effective and
to further evaluate its safety
Phase III Experimental vaccine is given to large groups
of people (1,000-3,000) to confirm its
effectiveness, monitor side effects, and compare
to commonly used treatments.
Phase IV Post-marketing studies determine a drug’s risks,
benefits, and optimal use.
Source: http://clinicaltrials.gov/ct2/info/understand.of HIV/AIDS vaccine trials and other innovative research
studies.
This case study focuses on 8 fellowships during this
period, each lasting 6 months. To select the fellowships
we reviewed job descriptions to find projects focused
mainly on clinical trial capacity building, and included
only fellowships completed by 2009. Most Fellows
worked at Regional and Country Offices or with the
clinical trial centers in Uganda, Kenya, and South
Africa, often administered by partner organizations (see
Figure 1). In some cases, Fellows also traveled to other
locations such as Zambia and Rwanda. Earlier Fellows
worked mostly with the field centers (IAVI partners) to
increase their capacity to perform international standard
clinical trials, while more recent Fellows focused their
efforts on how IAVI itself could strengthen capacity to
manage multiple trials at once.Methods
Data was collected for this case study in two ways. First,
we reviewed Pfizer administrative records of fellowships,
including job descriptions, online journals (blogs) writ-
ten by Fellows during their six-months in the field, final
fellowship reports, annual individual evaluations of fel-
lows by supervisors and the fellows themselves, and an-
nual GHF program performance evaluations. In addition,
follow-up interviews were held with Fellows and IAVI staff
to probe for the long-term impact of GHF work and the
potential benefit of sending multiple Fellows over several
years – aspects which were never addressed in past indi-
vidual and program-level evaluations.
We made multiple efforts to contact all 8 Fellows but
were only able to interview 4: three had left the com-
pany and could not be located, and one was not available
to interview within the data collection period. Although
we could not conduct follow-up interviews with all
Fellows, we had detailed evaluation information on all
fellowships, often in the Fellow’s own words (e.g.
through blog entries).
We also interviewed 5 staff identified by IAVI as hav-
ing worked closely with individual Fellows and being
well informed about their projects. The interviews
asked Fellows and staff to describe IAVI’s level of devel-
opment and capacity building needs at the start of the
fellowships, GHF activities which seemed to have the
most impact on capacity building, and perceptions about
the structure, benefits, and challenges of the IAVI-GHF
partnership over time. Interviews were conducted in
August-September 2011. Our protocol did not include
interviews with staff of research partner organizations or
clinical centers; however, often the opinions of these
staff were documented in fellowship evaluation reports
or other administrative records.
Figure 1 IAVI Organizational Structure for HIV Vaccine Clinical Trials in Africa. Source: Authors, adapted from IAVI web site content and
journal entries by Pfizer Fellows.
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IAVI in 2005
In 2005, IAVI had limited research partners and clinical
centers in Southern and East Africa, and was heavily re-
liant on contract research organizations for trial-related
functions such as training and monitoring. While IAVI
had been involved in several scientific and epidemiologic
studies and had completed three HIV vaccine trials, the
organization did not have a lot of experience managing
multiple trials and trial centers at once. IAVI had
established small field offices in Uganda and Kenya, and
had one staff member working in South Africa. Often,
trial management functions were carried out by IAVI
staff operating from remote offices in New York,
Netherlands and Belgium.
According to Fellows who volunteered in 2005 and
2006, IAVI was well organized and had a clear vision
and mission. IAVI staff understood that in order to reach
their goal of expanding HIV/AIDS clinical trial research
in Africa, they needed to further develop the skills of Af-
rican investigators, approach new partner organizations,
and prepare research centers to meet the high standards
required for clinical trials. Although IAVI staff had the
expertise to conduct training and monitor multiple trials
simultaneously, the organization did not have adequate
resources to expand rapidly or to support the size of the
trials envisioned. To ensure the timeliness of trial pro-
gress, the integrity of data, and the safety of trial partici-
pants, IAVI needed to ramp up training, and bring trial
monitoring in-house.Lean staffing of field offices also meant that IAVI did
not have much back-up if anything went wrong. If a staff
member with a professional skill set was sick or unavail-
able, there was “no one ready to step into that person’s
shoes” without the need for extensive training. This situ-
ation is common to many non-profits, but in a time-
sensitive and highly technical field such as clinical re-
search, it is an especially important area of vulnerability.
Contributions to capacity building
According to Lough, et al. (2011), key areas of direct con-
tribution to capacity building by volunteers include: 1)
promoting intercultural understanding; 2) providing or le-
veraging additional resources such as supplies or money; 3)
extending service provision by acting as an “extra pair of
hands”; and 4) applying technical and professional skills.
Long-term, skilled volunteers tend to provide added
value in the latter two dimensions [14]; for example, by
filling critical short-term staffing needs or by providing
needed technical assistance, technology transfer, or staff
development activities. Table 2 lists the 8 Fellows who
worked in clinical trial capacity building and summarizes
their job descriptions. The main ways in which Fellows
applied their professional skills are described below.
Four areas of GHF technical assistance
Capacity building for clinical trials roughly can be di-
vided into four phases which are mutually reinforcing
(Table 3). First, during the start-up period the clinic
centers must be identified and operating procedures
Table 2 Capacity Building GHF Fellowships with IAVI
Fellows Country Year Position Job responsibilities
Fellow 1 South Africa 2005 Clinical Research Site Manager Setting up study operations manual (SOM) and conducting center
initiation activities and training for a 5-center Phase II trial in 3 countries
Fellow 2 Kenya 2005 Clinical Research Trainer Setting up clinical research centers, conducting training on
Good Clinical Practices (GCP)
Fellow 3 South Africa 2006 Sr. Clinical Research Associate Developed SOMs and modules for GCP training, prepared centers for
monitoring visits and audit
Fellow 4 Uganda 2006 Clinical Project Manager Conducted monitoring, initiation of centers, and training of study personnel.
Worked in Uganda and Zambia.
Fellow 5 Kenya 2007 Clinical Program Manager Helped in center initiation activities including writing standard operating
procedures, quality management plans, and preparing centers for inspection.
Created training plans and trained investigators and trial participants
Fellow 6 Uganda 2008 Clinical Trial Site Monitor Conducted GCP training, Clinical Research Associate (CRA) training. Developed
monitoring tools and conducted monitoring visits with CRAs. Provided
feedback and mentoring.
Fellow 7 Kenya 2009 Clinical Project Manager Conducted GCP training, created monitoring tools
Fellow 8 South Africa 2009 Data Manager Conducted a data management assessment, including documentation
of current processes for lab sample movement, and other data flows.
Made recommendations to IAVI board.
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each particular research study which may involve differ-
ent objectives, types of participants, safety concerns and
data collection needs. Secondly, staff involved with
current studies and possible future trials need to be
trained so that they are aware of how to protect trial
participants and comply with quality standards. Once
the set-up period is over, a third set of activities involves
building monitoring capacity (staff and systems) to as-
sure that centers are audit-ready at all times and can
demonstrate adherence to standards during regulatory
visits. Finally, as the volume of clinical trials grows, the
need to manage multiple clinical trials at once poses
additional challenges. Data management systems need to
be strong enough to organize, analyze, and allow access
to data by many kinds of users in timely, efficient ways.
IAVI GHF Fellows provided technical assistance in
these four areas: center preparation, training, monitor-
ing, and data management. Although all areas included
activities which benefited both IAVI and local partner or-
ganizations, the first two types of assistance tended to be
focused on local partners, while the latter two were oftenTable 3 Stages of Capacity Building for Clinical Trials
Phase Types of activities needed
Start up Assess center readiness, develop
standard operations guides
Training Train staff and others (as requested)
on Good Clinical Practice (GCP)
Monitoring Create supports and assure compliance
with quality standards
Management Design systems to manage multiple
clinical trials at oncetargeted toward IAVI itself. Examples of the activities
undertaken by Fellows in each area are described below.
Start up and center preparation
Fellows were involved in diverse activities to prepare
field centers to undertake specific studies and clinical
trials. Capacity strengthening included writing standard
operating procedures (SOPs) and study operations man-
uals (SOMs) adapted to research study protocol and the
centers themselves; conducting center initiation meet-
ings; and making on-site visits to review operations and
procedures in clinics. These activities were generally
undertaken by Fellows in 2005–2006, and sometimes
involved centers which had not done many research
studies, or which had never been involved in clinical re-
search or HIV vaccine trials. Fellows often had to travel
to other domestic and international locations; for ex-
ample, one vaccine trial protocol involved three South
African centers plus centers in Zambia and Uganda.
Training
Fellows have provided assistance in training, with the
topics evolving over time. At first, training focused on
Good Clinical Practice (GCP). Developed by the Inter-
national Conference on Harmonization (ICH), GCP is
an international ethical and scientific quality standard
for designing, conducting and reporting on trials involv-
ing human subjects. The GCP standard is meant to pro-
tect the rights and safety of participants in clinical
research studies, and to help ensure scientific integrity
and quality of findings. A basic understanding of GCP is
prerequisite for anyone involved in clinical trials, includ-
ing principal investigators, clinic support staff, monitor-
ing personnel, ethics boards, and community oversight
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personnel should also receive refresher training on a
regular basis.
Pfizer Fellows worked with IAVI staff to develop in-
house training modules and conduct GCP training for
center staff and others interested in receiving training
(e.g. advisory board members) in Kenya, South Africa,
Uganda, Rwanda and Zambia. In the past, IAVI had
relied on contract organizations to conduct training, a
strategy which ensured high quality but was expensive.
A regional director explained how GHF Fellows helped
IAVI change its training strategy and increase efficiency:
We used to outsource GCP trainings for the Africa
network, but at a significant cost. The Fellows helped
us to transition from this outsourced model to an in-
sourced operation. We fully made the transition and
no longer go outside for training resources. This has
meant tremendous cost savings for IAVI.
Although IAVI still needs to update training curricula
to keep it fresh, the role of IAVI local and central staff is
growing more important. “Basically we’ve optimized the
way we implement this required training,” said one IAVI
manager. “We don’t need GHF assistance in this area
anymore.” Another staff member concurred: “We now
have African CRAs (Clinical Research Associates) with
3–5 years’ experience. They have had training, they’ve
worked. They can do the job themselves.”
Monitoring
Clinical studies require monitoring to protect participant
safety and ensure integrity of data. Each monitoring plan
must be adapted to context and depends on the study’s
degree of risk, rate of enrollment of participants, experi-
ence of centers and principal investigators, etc. This pre-
sents a challenge for an organization like IAVI which is
monitoring multiple trials and trial centers at once.
Study managers and monitoring staff must make many
decisions about what to monitor, how communications
should be organized (including information shared by
telephone, e-mail, or during monitoring visits), and how
to handle deficiencies discovered during monitoring.
GHF Fellows worked with IAVI to develop monitoring
plans and train staff. A focus of Fellows was to instill the
principle that clinical research centers should be audit
ready at all times, instead of reacting with panic once a
regulatory visit is announced. Fellows helped IAVI to
prepare plans which were responsive to different regula-
tory authorities and funders, including the US National
Institutes for Health and others. They designed monitor-
ing forms which would allow automated data input, to
make it easier to track problems and compare centers.
Some Fellows adapted training tools from Pfizer andfrom regulatory authority web sites. An IAVI regional
director spoke about the result of GHF assistance in the
Africa region:
In the last 6 months alone, we have vaccinated 300
people and we are monitoring it all ourselves, as
opposed to using contracted monitors. So this is an
example of how the capacity building has been not
just for the local partners, but for IAVI Africa as well.
An additional challenge was to inculcate the belief that
monitoring is important and that everyone’s participa-
tion is needed. Developing this type of commitment is
important to support and sustain organizational capacity
[26]. One Fellow explained:
Although the monitors had a good base of knowledge
of GCP, they didn’t yet see the big picture. They knew
the role and job description, but they didn’t realize
how every little thing they have to review, every note
they take, can make a difference. I tried to help them
discover the true extent of the monitor’s
responsibilities when it comes to overseeing the trials.
Teaching monitors how to give feedback is especially
important in cultural settings where authority is central-
ized and power differentials may make it difficult for
someone who is not the principal investigator to point
out mistakes or give constructive criticism [5]. A Fellow
recounted how she would mentor IAVI staff during
training, to help build their confidence in working as a
monitor in this context. “Your best argument is know-
ledge,” she would say. “If you aren’t certain, try to get
the information.” She wanted the monitors to under-
stand that giving feedback did not mean you were
“attacking” the research team, but that it is part of the
monitor’s job to “address the physician, to ask him to clar-
ify. Not to let it go.” In a 2007 evaluation report, an IAVI
supervisor described the impact of this mentoring [25]:
[The Fellow] introduced the idea that monitoring
would start by looking at the last feedback letter, and
making sure that those identified problems had been
addressed. If they hadn’t, then the team would have a
chance to address them while the monitor was
present…It is very hard to give criticism in a way that
causes action without [causing] resentment. But this is
what the GHF was very good at, and we learned how
the systems can support this.
Data management
Investment in research infrastructure, including infor-
mation systems, is another critical aspect of sustainable
capacity building [11]. By 2009, IAVI’s investments in
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growth in clinical trial enrollment—and the data that
accompanied this growth, especially data related to spe-
cimen tracking and association of research data with
specimens. This made it hard for IAVI to take advantage
of the data they had collected, as they lacked capacity to
systematically collate, synthesize, conduct queries, and
report on these data. To address these needs, IAVI created
a job description for a Fellow to assess the data man-
agement function and make recommendations. The
GHF Fellow selected for this position summarized the
critical importance of data management for capacity
building:
Data underlie everything in clinical trials. If you don’t
fix the plumbing then you won’t get the water. Data
flow, data exchange, access of data, analysis of data-
-people can only make changes once they know how
things are unfolding, and they know this based on
data. If they get the data at the right time, they can
alter the way the clinical trial is happening.
The Fellow began by documenting how data were
collected and flowed through the system based on field
visits and interviews. The resulting process maps pro-
vided a more global view of how organizational units
interacted and highlighted gaps and redundancies. IAVI
staff found the maps useful: one manager said the
process maps were referred to in new staff orienta-
tions, while another IAVI data manager described
other benefits:
[Five months after the Fellow’s departure] we
created a “sample management” task force which
was trying to streamline and improve the way we
managed laboratory samples. We began with the
process map that [the Fellow] had done: it gave us
a “coat hanger” of sorts, a place to start. We
viewed each process and said ‘Ok, so this is how it
works now. Where can we improve this?’ And we
completely re-designed the process for sample
tracking. The result is a simplified system that
makes it much easier to track these samples in the
database. It uses less forms and paper, less back
and forth: it is a more efficient process now, used
in all sites in Africa. And we started with [the
Fellow]’s process maps.
The Fellow’s work also raised awareness of the need to
take a broad and strategic view of data management ac-
tivities. The IAVI data manager explained:
We thought we needed a data warehouse, and we
decided that we were going to do it. But it didn’t fit intoany longer term strategy, so, as the Fellow predicted, a
year later nothing is happening. The Fellow really made
that a point, the idea that we have to look at things
overall, to take a broader view. We don’t have a
strategy, so the initiative didn’t get traction.
Another IAVI staff member noted how the GHF had
offered a longer-term and more strategic perspective:
“That ‘view from-afar’ was very helpful. Sometimes at
IAVI we don’t see the woods for the trees. The Fellow
had this more objective view. Often the Fellow could
provide simple solutions to problems that to us seemed
very complex.”
Although the Fellow’s final report was presented to the
IAVI senior management team, not all the recommenda-
tions could be implemented. For example, one important
recommendation was the need to recruit someone to
oversee all data management activities across the Re-
search and Development function, but this was not done
due to cost considerations and disagreement on how to
integrate the new position into the organizational struc-
ture. At the same time, another IAVI director believes
this Fellow’s work has really guided how IAVI collects
data and adapts to change:
The senior management team is now aware of where
we lack capacity, and since then we have employed
additional people to manage data. The report opened
everyone’s eyes to think about how we are collecting
data, where we are putting data, and how we are
sharing it. Things won’t change overnight, but people
are much more aware of the issues now. Every time
there’s something new to consider, we refer to those
diagrams [of work process flow].
Factors which promote effectiveness
We asked the Pfizer Fellows and IAVI supervisors to re-
flect on what factors in particular helped make their
partnership and the international volunteering program
more effective. We also analyzed Fellowship documenta-
tion to pinpoint variables which seemed to affect change.
The factors identified included:
 similarities in mission between IAVI and Pfizer;
 the expertise, experience, and perspective of Fellows;
 openness;
 focus on organizational learning; and
 trust-building or motivation.
Figure 2 depicts the relationships among these factors.
Similarities in mission
Similarities in the types of activities undertaken by Pfizer
and IAVI staff, working to develop new medicinal
•  More specific job description, 
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•  Stronger in-country support for 
Fellows
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Figure 2 Model of Factors Predicting Success of ICV Partnership.
Vian et al. BMC Health Services Research 2013, 13:378 Page 8 of 12
http://www.biomedcentral.com/1472-6963/13/378products, allowed Fellows to be more effective. “We
understood them and they understood us, because our
missions and our backgrounds were similar,” said one
Fellow. “We were able to start right away and to be help-
ful sooner, because the things they wanted us to do are
things we do every day in our work.” Where GHF are
assigned to work for organizations whose mission is not
so similar, or where the job description requires a
stretch, the learning curve can be greater. For example,
a Fellow working with a humanitarian NGO in Northern
Kenya was asked to create a database to manage refugee
information. While the Fellow had strong skills in data-
base management, it took her some time to get to know
the organization and the issues. The learning curve for
meeting the challenges of clinical trial management was
shorter for Pfizer Fellows assigned to IAVI.
Expertise, experience, and perspective of fellows
A second factor mentioned by many informants was the
expertise, experience, and broad perspective of Fellows.
Non-profits like IAVI are stretched and may not always
have expertise available at the time and place it is needed.
One way to cover these gaps is to recruit a Fellow who can
quickly contribute scarce skills or knowledge. As one Fel-
low remarked, “Pfizer has people like me in the thousands,
but small NGOs do not. At the same time, the NGOs are
nimble and agile institutions: this allows them to use our
expertise well when they have it.” Another way in which
Pfizer Fellows’ expertise has been tapped is when a Fellow
steps into a job which is temporarily vacant. An IAVI
supervisor described how this happened in South Africa:
The timing couldn’t have been better, because as soon
as she came, IAVI’s senior Clinical Research Associate(CRA) fell ill. The Fellow was able to take over for six
months, just like nothing had happened. She had a big
and fast learning curve, but she was so senior that she
really knew what she was doing, she knew exactly
what needed to happen. Without the Fellow, we
would have fallen behind in the protocol; the study
would have been delayed.
Working in South Africa, the Fellow compiled an
SOM for a new trial and helped two centers to begin re-
cruitment of trial participants. She trained staff on GCP
and helped them prepare for audit and inspections. The
Fellow described the advantage of using highly experi-
enced volunteers, “We can hit the ground running,
doing things that, if IAVI had to hire staff, they would
have had to train people to do… None of us are novices.
Having that experience is very helpful for IAVI.”
IAVI staff also mentioned how experience, maturity,
and being able to handle uncertainty make Fellows
more productive. IAVI has learned to be cautious about
accepting an otherwise technically-qualified Fellow who
doesn’t have relevant experience living or working in a
developing country. “If a Fellow has never traveled,
never come to Africa, then we will have reservations
about them going to a rural site,” said one supervisor.
Finally, IAVI staff noted that the Fellows’ leadership
skill was important to their effectiveness, i.e., their ability
to bring a broader perspective, scanning the environment
beyond the work plan. Pfizer Fellows helped IAVI step
back from the day-to-day “fire-fighting” and think about
strategic steps needed to realize IAVI’s mission. As one
Fellow explained, “[Pfizer employees] are used to looking
for issues, anticipating, scanning the situation. We are
used to identifying issues before they occur. IAVI wasn’t
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have enough people. So we could help them do that.”
Open attitude and desire to improve
Literature suggests that organizational readiness for
capacity building enables better results. Organizational
readiness includes organizational willingness to question
their current practices and commitment to participate
actively in capacity building activities [9]. A third factor
which was important to the effectiveness of the Pfizer-
IAVI partnership was an open attitude and desire to
improve on the part of IAVI and the local partner orga-
nizations. Fellows noted IAVI’s interest in receiving ad-
vice to improve their operations, their “teamwork, spirit
of motivation, supportive and sympathetic principal in-
vestigators” at the clinic centers. “IAVI staff took feed-
back well and acted on recommendations thoughtfully,”
said one Fellow. Another Fellow noted how IAVI’s inter-
est in improvement extended to interactions with part-
ner organizations: “IAVI would listen to ideas for how a
change in processes could help their partner organiza-
tions. They knew they could only accomplish things if
the partner organizations are effective, so these kinds of
changes helped IAVI too.”
Even the most qualified and experienced international
volunteers cannot build capacity if the environment is
not receptive. According to GHF Fellows, the effective-
ness of their efforts depended on the caliber of African
staff at the research centers. Fellows worked with highly
motivated staff at these clinic centers, carefully selected
people who really wanted to make a difference. They
were trying to work with the local community. There
was a huge amount of education needed in the commu-
nity and many misconceptions about HIV/AIDS. So the
staff commitment was important.
Focus on organizational learning
Both Pfizer and IAVI learned from the experience of
early Fellows, making changes to improve support of
Fellows. IAVI tried to improve their readiness to receive
volunteers in many ways. They arranged safe accommo-
dations ahead of time, increased budgets to be sure that
Fellows would have easy mobility, and engaged their
own staff in orienting and working with the Fellows.
IAVI staff made efforts to seek feedback from Fellows on
how they could improve field program design and over-
all organization. Over time, these changes allowed Fel-
lows to provide substantive contributions earlier in the
fellowship period. One IAVI supervisor explains:
The fact that Johannesburg office was only established
in 2006 has bearing on the support we were able to
provide for the first Fellow when she came in 2005.
It was a challenge for her to be in place without anestablished IAVI office. We hadn’t thought through
how to handle the fellowships. IAVI learned a lot of
lessons and changed things so that subsequent
Fellows could be more effective.
Later Fellows confirmed that these improvements
eased their transition. For example, although it took
early Fellows several days to get an apartment and a cell
phone, later Fellows found that IAVI had arranged suit-
able living space and met them at the airport with a cell
phone pre-programmed with staff contacts.
Another area of organizational learning was in defin-
ing job descriptions, Fellow selection, and matching.
IAVI staff said they learned to make the job descriptions
very clear, and to be sure that the tasks were feasible to
accomplish in the time allowed. “Now we create defined
deliverables,” said one supervisor. “We want to make
sure that the Fellows are aware of what we expect.” Both
IAVI and Pfizer GHF program staff recognize that hav-
ing a good match between the Fellow and the host
organization is a critical success factor. One Fellow
explained, “The organization’s need has to match with
the talent from Pfizer. This is the most important thing.
If they don’t have the right person to solve the problem,
there will be disappointment on both sides.” Another
Fellow agreed, stating that NGOs need to take the time
to make the right match between what a particular
Fellow knows how to do, and the kind of help the
organization needs. In this way they can “tweak” the as-
signment to take best advantage of the Fellow’s help:
“When ‘match’ meets ‘talent and passion’, things turn
out right.”
GHF program staff and individual Fellows also took
actions to improve the program based on past experi-
ence. For example, earlier Fellows made themselves
available to meet with Fellows just going out, to share
experiences and help the new Fellows understand the
institutions, locations, and environment. One Fellow
explained, “A Fellow who was going to this location after
me was very afraid of the security issues. I spoke at
length to her, to give her practical suggestions and to re-
assure her.”
Fellows held debriefings with IAVI at the end of their
stay, to discuss lessons learned which might affect the
design of the next Fellow’s job description. In such meet-
ings, the Fellow and IAVI staff discussed positives and
negatives of the fellowship, what could be done better,
and how IAVI and GHF program could make changes to
further maximize the capacity building contributions of
Fellows. “Part of what is important to this is that the
Fellows talk with IAVI, at the start and throughout,” ob-
served one Fellow. “We have to relate our experiences to
their situation and their plans. We talk about what we
have done. You keep enlarging the picture.”
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munication channels and facilitate learning. The pro-
gram added guidance to help partner organizations
design more specific job descriptions, helped Fellows to
blog about their experiences, and created a GHF alumni
network to promote information sharing.
In designing job descriptions for Fellows, IAVI staff
often sit down together as a team. Sometimes they can
design fellowships to build on one another, but this is
not easy due to timing and the candidates available. Yet,
one Fellow noted that even if each Fellow has somewhat
different skills or experience and works on a different
problem, they are contributing something toward the
overall goal of capacity building: “It is a bit like a jigsaw
puzzle. We each put a little into it, and it makes the big
picture.”
Trust
Trust is the basis of any stakeholder collaboration and
enhances capacity building [3,6,9,12]. The organization
receiving a Fellow needs to believe that the Fellow has
the organization’s interests in mind, and has something
of value to offer. Trust is also a quality that is personal.
Just because an organization has had several Fellows,
does not mean they will trust every Fellow. It is people
working together during a fellowship who generate trust.
As one Fellow noted, “You have to go beyond their du-
ties to get to know the people. Only then will they
accept what you are saying.”
While the focus of this case study is the impact of
corporate volunteering in building NGO capacity, the
Fellows who participated in the program also gained
skills and experience working in new regions or a new
therapeutic area. Fellows learn to adapt to challenges
such as lack of electricity, travel mishaps, and a “differ-
ent beat” in the work place--logistical constraints which
are a major challenge for researchers in low-income set-
tings [4]. For example, one Fellow stated that “I learned
that I needed to start earlier to get things done, and to
accept that some things were going to happen last
minute.” Another area of learning was about culture dif-
ferences. “You can ask questions about sexual behavior
in Kenya that you can’t ask in Uganda,” said an IAVI re-
gional director. “Everywhere we work the cultures are
different. The best Fellows see this as an opportunity to
learn.” A Fellow who worked in South Africa described
how her fellowship helped her appreciate how cultural
values influence clinical trials:
The concept of informed consent is that the patient
can withdraw at any time. Yet, when I was talking to
colleagues in East Africa, they didn’t see it like that.
They thought, ‘If we are spending this amount of
money, we want these patients to continue. Why areyou telling them they can withdraw? That gives the
impression you are not serious about what you are
doing.’ Once you understand these cultural differen-
ces, you learn how to explain things in a different
way, so they can see why you are insisting on doing
this strange thing that seems wrong to them.
Nowadays, pharmaceutical companies are conducting
trials all over the world, in places like India, China.
I have not been to those countries, but if I am asked
to go, I can imagine that similar sorts of cultural
issues will be important.Discussion
Developing capacity leads to greater ability to perform
useful research [11]. The partnership between IAVI and
Pfizer was successful in building capacity for clinical tri-
als in the areas of center preparation, training, monitor-
ing, and data management systems. Fellows helped IAVI
and local partner staff to develop clinical trial proce-
dures, conduct GCP training, and design monitoring
systems to assure that trial centers are audit ready at all
times. They helped IAVI in periods of growth and transi-
tion: expanding from doing small, sequential trials to
running large trials simultaneously in multiple centers
and countries; transitioning from contracted out training
and monitoring services to using less expensive but
equally high quality in-house capacity; anticipating data
management needs and streamlining processes to share
information more efficiently and effectively.
The successes in the partnership can be traced to mul-
tiple factors, including similarities in mission between
IAVI and Pfizer, which meant that Fellows needed less
time to become productive; the high levels of expertise
and experience which Fellows could draw upon, and the
broad perspective they could offer to IAVI as they helped
the NGO to improve or expand into areas of opportunity;
attitude and motivation of IAVI and the local partners,
who were open and willing to work on problems and try
new approaches; and an orientation toward organizational
learning on the part of IAVI and Pfizer’s GHF program,
which allowed both organizations to adapt and improve
the partnership based on past experience.
Over the five years of collaboration, these factors and
the positive results achieved built greater trust which in
turn reinforced the model. As Fellows and IAVI staff
and partners had positive experiences working together,
and as IAVI achieved meaningful improvements in their
capacity to achieve their goals, the partners were more
willing to experiment, work harder, and test ways to im-
prove the program even more.
Some elements of the Pfizer-IAVI partnership’s success
reflect factors identified in the literature on capacity
building; for example, IAVI’s readiness for capacity
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allowed in-depth understanding of needs and time to
develop capacity, and the adaptation of capacity building
strategies to the specific needs of vaccine research.
Another influence on the success of the IAVI-Pfizer
collaboration is how IAVI thought about the assistance.
The drive to use corporate volunteer assistance seemed
to come not from any specific gap that IAVI was experi-
encing, but from the desire to learn; i.e., ‘What do we
want to know from industry?’ , ‘How can GHF be a cata-
lyst for capacity building in this context?’ Given this mo-
tivation, capacity building assistance was not perceived
as part of a linear plan but rather as a mosaic: a mechan-
ism for “opportunistic improvement” guided by the
organizational mission and the experience, skills and
perspective of the Fellows themselves. The importance
of this type of ‘organizational learning’ orientation and
its link to capacity building has not been previously
noted in the literature. Health professionals designing
public-private partnerships in other contexts may want
to consider approaches to deliberately promote an
organizational learning culture and take advantage of the
fertile environment provided for development.
All this is not to say that the partnership did not experi-
ence bumps and disappointments along the way. Some of
the challenges described by the participants included lack
of follow-up after a fellowship, an individual Fellow who
didn’t work out, and staffing turnover at IAVI.
Several Fellows and IAVI staff mentioned the difficulty in
arranging for sequential Fellowships that would build on
each other. “It would have been helpful if someone came
right after me, to implement the recommendations I helped
generate,” said one Fellow. Yet, sequential fellowships are
hard to arrange. “We haven’t always had a lot of people to
choose from” said an IAVI regional director, “because often
the job description is very specific, and finding a match is
not guaranteed.” The GHF program has been re-designed
in recent years to encourage more sequential fellowships, a
strategy which may help address this problem. As an alter-
native to arranging sequential fellowships, the program
might consider longer fellowships or extensions as a way of
ensuring that important projects are completed.
IAVI has had very good experience to date in selection
of Fellows; however, in one case a Fellow did not achieve
the results expected. To minimize unproductive fellow-
ships, Pfizer has tried to strengthen screening of candi-
dates and helps recipient organizations to develop clear
and specific job descriptions. IAVI has also taken action to
increase internal participation in the selection process and
to interview candidates more carefully. Although IAVI
managers thought having the occasional bad match may
be unavoidable, one Fellow thought it was important to de-
sign a system for early termination of fellowships that don’t
seem to be working: “There should be a way to terminatethe relationship, so as not to waste everyone’s time and
make others discouraged who hear about the waste.”
Finally, inadequate staffing in the organization receiv-
ing the Fellow can make it difficult to achieve results.
One Fellow noted that the South Africa regional office
was currently operating with one-third the staff it had in
2009. What this means is that people are busy getting
their work plan done, and don’t have time to “step out
of the box, to take time to think”. This can be an im-
pediment to organizational learning.Limitations
It is clear that the issue of capacity building and PDPs is
much broader than the remit of this article [27]. The
focus of this study is the capacity building contribution
made by Pfizer Fellows to IAVI rather than the contribu-
tion made by IAVI to the developing countries in which
it is active. The latter topic is written about in papers by
Chataway and Hanlin [28] and others [29].
Our study was limited by several factors. As mentioned
earlier, we were only able to re-interview four of the eight
Fellows, though we did analyze archival material (e.g. job
descriptions, online journal entries, prior evaluation re-
ports) on each of the eight fellowships. In addition, we
limited the study to Fellows whose job descriptions were
directly related to clinical research capacity building, thus
excluding other Fellows whose work indirectly supported
capacity building (for example, several IAVI staff men-
tioned a Fellow who mentored laboratory staff in Flow
Cytometry, including one laboratorian who is now viewed
as a regional resource because of his expertise). Finally,
given that our purpose was to characterize the relationship
between the international Fellows and IAVI as an
organization, we conducted interviews with Fellows and
IAVI staff. However, Fellows also worked with local Clin-
ical Research Centers to build capacity in various areas.
Perspectives of key CRC staff such as directors and Prin-
cipal Investigators who interacted with the Fellows
could have provided further information on capacity
strengthening for these IAVI partners. This would be
an interesting topic for further study.Conclusion
International corporate volunteering programs like the
Pfizer Global Health Fellows program can help build
stronger capacity for international and local NGO part-
ners. By developing standard operating procedures, ensur-
ing that monitoring and regulatory compliance systems
were in place, training African investigators and commu-
nity members, and engaging in other systems strengthen-
ing activities, GHF has helped IAVI to accelerate vaccine
development activities in the field while also developing
the organization’s capacity to manage change in the future.
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nerships to further public health goals may wish to con-
sider adding an international volunteering component as a
capacity strengthening strategy to complement other ef-
forts. More work is needed to document these types of
programs and their impact over time.
Endnote
aAn AIDS vaccine is defined as “an experimental strat-
egy that aims to teach the body’s immune system how to
fight HIV to reduce the risk of infection or to reduce
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